Virus

Association study of lipoprotein genetic markers and HIV

Impact of pharmacogenetic markers of CYP2B6 in HIV-Tuberculosis

Would a CYP2B6 test help HIV patients being treated with efavirenz

High plasma Efavirenz concentration and CYP2B6 polymorphisms in Thai HIV-1 infections

Pharmacogenetics of hepatitis C

Dysregulation of innate immunity in HCV genotype 1 IL28B unfavorable genotype patients

The dual role of pharmacogenetics in HIV treatment

ABCB1 variation and treatment response in AIDS patients-initial results of the Henan cohort

Association of high T allele frequency of CYP2B6 G516T polymorphism among ethnic south Indian HIV-infected patients with elevated plamas efavirenz and nevirapine

CYP2B6 and CYP2A6 polymorphisms are independent predictors of efavirenz plasma concentration in HIV-infected patient

CYP2B6 CYP2A6 and UGT2B7 genetic polymorphisms are predictors of efavirenz mid-dose concentration in HIV-infected patients

CytochromeCYP2B6 and CAR polymorphisms are associated with early discontinuation or Efavirenz-containing regimens

In silico prediction of efavirenz and rifampicin drug-drug interaction considering weight and CYP2B6 phenotype

Population pharmacokinetic-genetic model for optimization Efavirenz therapy in caucasian HIV-infected patients

Relationships between CYP2B6 polymorphisms and pharmacokinetics following single dosis of nevirapine or efavirenz in African Americans

Tribal ethnicity and CYP2B6 genetics in Ugandan and Zimbabwean populations in UK- implications for efavirenz dosing in HIV infection

Regresar al Acervo